Price controls will slow drug innovation
Navigating the regulatory regimen is “hugely expensive,” said Ian Adams, Sacramento director of the R Street Institute, a right-of-center think tank. This is “some of the most sophisticated science going on in the world” and researchers don’t know if any investment will pay off.
Featured Publications
Low-Energy Fridays: Emergency Orders Are Not a Grid Reliability Strategy
Safer Solutions: What Do Supply and Demand Have to Do with Drug Policy?
The Diddy Verdict Exposed the Gaps—Now Policy Must Catch Up
How Should We Think of the OBBBA’s Electricity Subsidy Repeal?
Netflix’s “Adolescence” Exposes the Digital Crisis Reshaping Youth and Justice